Find Lilly Clinical Trials | Learn About Our Research - Lilly Trials
Lilly's new Trial Connect feature allows you to search for clinical trials that may be the best fit for you or a loved one. Simply answer a few questions to find which Lilly trials may be the best match.
A Study to Investigate the Effect of Lepodisiran on the Reduction …
Answer a few questions to see if you meet key criteria for this study. What the trial is testing? Could I receive a Placebo? How long will I be in the trial? The study is likely to last 4-5yrs. It will continue until all the study information has been collected.
Clinical Trials and Research | Eli Lilly and Company
A clinical trial is a research study that tests a medicine or therapy in people to help us understand how well it works and how safe it is. Clinical trials contribute to the advancement of medicine with the goal of making life better for people.
Find a Lilly Clinical Trial - Lilly Trials
Search Lilly clinical trials to find an appropriate trial near you or a loved one, or sign up to receive alerts on Lilly trials.
Expanded Access - Eli Lilly and Company
At Lilly, we understand that sometimes people may seek access to investigational medicines before they are reviewed and approved by a regulatory authority, such as the U.S. Food and Drug Administration (FDA). This can be done in two ways - through clinical trials and expanded access.
Clinical Trials | Discovery | Eli Lilly and Company
A clinical trial is a scientific study that helps determine if and how a medicine works in people. Every clinical trial participant provides valuable information that might help improve medical research and knowledge.
News Release - Eli Lilly and Company
Jun 26, 2023 · In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% at 48 weeks. Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program.
AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year
2 days ago · A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein (a) – a risk factor for cardiovascular disease – by up to...
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high ...
INDIANAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein (a) [Lp (a)], a …
Lilly's Zepbound® (tirzepatide) superior to Wegovy® …
INDIANAPOLIS, Dec. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: ... (OSA) or cardiovascular disease, who did not have diabetes. The trial randomized 751 participants across the U.S. and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of Zepbound (10 mg or 15 mg) or Wegovy (1.7 mg or 2.4 mg). The primary objective of the ...